Skip to main content
Clinical Trials/CTRI/2023/11/059609
CTRI/2023/11/059609
Not yet recruiting
Phase 3

Metabolic Resuscitation in Pediatric Septic Shock Using HAT (Hydrocortisone, Ascorbic acid and Thiamine) Therapy an Open Label Randomized Controlled Trial

All India Institute of Medical Sciences0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: O- Medical and Surgical
Sponsor
All India Institute of Medical Sciences
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Illness \-Admitted to PICU treated for septic shock (fluid refractory shock)
  • Treatment Received inotropes for at least 2 h
  • Consent Parental/caregiver consent prior to or after enrolment
  • (Definitions of surviving sepsis campaign 2020 will be followed for diagnosis of septic shock)

Exclusion Criteria

  • 1\.Age Preterm babies born \<34 weeks gestation that have a corrected age of \<28 days
  • 2\.Treatment \- Received inotropes for \>24 h pre\-enrolment
  • 3\.Patient is receiving treatment for a systemic fungal infection or has documented strongyloides infection at the time of randomization
  • 4\.Patient undergoing active chemotherapy for cancer treatment
  • 5\.Co\-morbidities •Fulmonant Myocarditis, Congenital heart disease
  • 6\.Chronic hypertension due to cardiovascular or renal disease, requiring regular antihypertensive treatment.
  • 7\.Known chronic kidney disease (defined as requiring Renal Replacement Therapy)
  • 8\.Known chronic hepatic failure
  • 9\.Known diseases affecting the steroid axis, including pituitary disease, congenital adrenal hypoplasia, Cushing or Addison’s
  • 10\.Known glucose\-6 phosphate dehydrogenase (G\-6PD) deficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials